Trillium Therapeutics Inc (TRIL)

Toronto
23.33
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    23.25/23.40
  • Day's Range:
    23.22 - 23.45

TRIL Overview

Prev. Close
23.22
Day's Range
23.22-23.45
Revenue
10K
Open
23.22
52 wk Range
7.48-24.41
EPS
-0.68
Volume
0
Market Cap
2.45B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
60,423
P/E Ratio
-
Beta
1.92
1-Year Change
189.1%
Shares Outstanding
104,995,125
Next Earnings Date
-
What is your sentiment on Trillium Therapeutics?
or
Vote to see community's results!

Trillium Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Trillium Therapeutics Inc Company Profile

Trillium Therapeutics Inc Company Profile

Employees
0
Market
Canada
  • Type:Equity
  • Market:Canada
  • ISIN:CA89620X5064
  • CUSIP:89620X506

As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Cambridge, Massachusetts. As of November 17, 2021, Trillium Therapeutics Inc. operates as a subsidiary of Pfizer Inc.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary